Filing Flows › CV Sciences (CVSI) › Q1 2026 › vs Q4 2025
CV Sciences (CVSI) Q1 2026 vs Q4 2025 (quarter over quarter)
CV Sciences's revenue fell $112K (-3%) from $3.3M in Q4 2025 to $3.2M in Q1 2026.
CV Sciences, Q1 2026: revenue $3.2M (-11% year over year), operating margin -10.0%, net loss $643K, operating cash flow $101K. The chart draws each line against Q4 2025, the increases inside each band.
Margins
| Q1 2026 | Q4 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 3.1% | -11.0% | +14.0 pts |
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.2M | $3.3M | −$112K | -3% |
| Net loss | $643K | $206K | $437K | +212% |
| Costs & expenses | $3.8M | $3.5M | $325K | +9% |
| Operating costs | $3.5M | $3.4M | $131K | +4% |
| Interest & other, net | $325K | $129K | $196K | +152% |
| Cost of revenue | $1.6M | $1.6M | −$3K | -0.2% |
| Research & development | $18K | $18K | $0 | 0% |
| SG&A | $1.9M | $1.7M | $134K | +8% |
| Operating cash sources | $744K | −$148K | $892K | — |
| Depreciation & amortization | $23K | $21K | $2K | +10% |
| Share-based compensation | $148K | $123K | $25K | +20% |
| Working capital & other | $573K | −$292K | $865K | — |
| Net loss absorbed | $643K | $206K | $437K | +212% |
| Operating cash flow | $101K | −$354K | $455K | — |
| Free cash flow (OCF − capex) | $98K | −$363K | $461K | — |
| Capital expenditures | $3K | $9K | −$6K | -67% |
Questions
How much did CV Sciences's revenue grow quarter over quarter in Q1 2026?
CV Sciences's revenue fell $112K (-3%) from $3.3M in Q4 2025 to $3.2M in Q1 2026.